These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29892082)

  • 1. Linkers for protein degradation.
    P Chamberlain P
    Nat Chem Biol; 2018 Jul; 14(7):639-640. PubMed ID: 29892082
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted protein degradation and the enzymology of degraders.
    Fisher SL; Phillips AJ
    Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An E3 ligase guide to the galaxy of small-molecule-induced protein degradation.
    Jevtić P; Haakonsen DL; Rapé M
    Cell Chem Biol; 2021 Jul; 28(7):1000-1013. PubMed ID: 33891901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
    Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
    Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein degradation: Prime time for PROTACs.
    Deshaies RJ
    Nat Chem Biol; 2015 Sep; 11(9):634-5. PubMed ID: 26284668
    [No Abstract]   [Full Text] [Related]  

  • 6. Discovery of Small Molecule WWP2 Ubiquitin Ligase Inhibitors.
    Watt JE; Hughes GR; Walpole S; Monaco S; Stephenson GR; Bulman Page PC; Hemmings AM; Angulo J; Chantry A
    Chemistry; 2018 Dec; 24(67):17677-17680. PubMed ID: 30207403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Protein Degradation: from Chemical Biology to Drug Discovery.
    Cromm PM; Crews CM
    Cell Chem Biol; 2017 Sep; 24(9):1181-1190. PubMed ID: 28648379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haven't got a glue: Protein surface variation for the design of molecular glue degraders.
    Kozicka Z; Thomä NH
    Cell Chem Biol; 2021 Jul; 28(7):1032-1047. PubMed ID: 33930325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for Cullins and RING component inhibition: Targeting E3 ubiquitin pathway conductors for cancer therapeutics.
    Shafique S; Ali W; Kanwal S; Rashid S
    Int J Biol Macromol; 2018 Jan; 106():532-543. PubMed ID: 28802844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monomeric Targeted Protein Degraders.
    Hanan EJ; Liang J; Wang X; Blake RA; Blaquiere N; Staben ST
    J Med Chem; 2020 Oct; 63(20):11330-11361. PubMed ID: 32352776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
    Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
    ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel approach for characterizing ubiquitin E3 ligase function.
    Marblestone JG; Suresh Kumar KG; Eddins MJ; Leach CA; Sterner DE; Mattern MR; Nicholson B
    J Biomol Screen; 2010 Dec; 15(10):1220-8. PubMed ID: 20864734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding Protein-Protein Interactions: Essential Players in (Patho)physiology (Part 2).
    Wilson AJ; Gunning PT
    ChemMedChem; 2016 Apr; 11(8):732-3. PubMed ID: 27061459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendrimer space exploration: an assessment of dendrimers/dendritic scaffolding as inhibitors of protein-protein interactions, a potential new area of pharmaceutical development.
    Mignani S; El Kazzouli S; Bousmina MM; Majoral JP
    Chem Rev; 2014 Jan; 114(2):1327-42. PubMed ID: 24127777
    [No Abstract]   [Full Text] [Related]  

  • 15. Blocking an N-terminal acetylation-dependent protein interaction inhibits an E3 ligase.
    Scott DC; Hammill JT; Min J; Rhee DY; Connelly M; Sviderskiy VO; Bhasin D; Chen Y; Ong SS; Chai SC; Goktug AN; Huang G; Monda JK; Low J; Kim HS; Paulo JA; Cannon JR; Shelat AA; Chen T; Kelsall IR; Alpi AF; Pagala V; Wang X; Peng J; Singh B; Harper JW; Schulman BA; Guy RK
    Nat Chem Biol; 2017 Aug; 13(8):850-857. PubMed ID: 28581483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?
    Thiel P; Kaiser M; Ottmann C
    Angew Chem Int Ed Engl; 2012 Feb; 51(9):2012-8. PubMed ID: 22308055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paving the way to targeting HECT ubiquitin ligases.
    Zinzalla G
    Future Med Chem; 2015; 7(16):2107-11. PubMed ID: 26510616
    [No Abstract]   [Full Text] [Related]  

  • 18. Ubiquitin Drug Discovery and Diagnostics Conference - targeting E3 ligases.
    Johnston JA
    IDrugs; 2010 Oct; 13(10):695-7. PubMed ID: 20878590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tipping the MYC-MIZ1 balance: targeting the HUWE1 ubiquitin ligase selectively blocks MYC-activated genes.
    Schaub FX; Cleveland JL
    EMBO Mol Med; 2014 Dec; 6(12):1509-11. PubMed ID: 25368331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells.
    Offensperger F; Tin G; Duran-Frigola M; Hahn E; Dobner S; Ende CWA; Strohbach JW; Rukavina A; Brennsteiner V; Ogilvie K; Marella N; Kladnik K; Ciuffa R; Majmudar JD; Field SD; Bensimon A; Ferrari L; Ferrada E; Ng A; Zhang Z; Degliesposti G; Boeszoermenyi A; Martens S; Stanton R; Müller AC; Hannich JT; Hepworth D; Superti-Furga G; Kubicek S; Schenone M; Winter GE
    Science; 2024 Apr; 384(6694):eadk5864. PubMed ID: 38662832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.